Lung Cancer Screening: Are You Ready?

WENDY H. VOGEL, MSN, FNP, AOCNP*

Screening for lung cancer is now recommended for certain people at high risk for the development of this malignancy. Currently, there is no evidence that other risk groups should be screened.

RISK FACTORS AND SMOKING CESSATION

The National Comprehensive Cancer Network (NCCN) Guidelines define persons at high risk of lung cancer as those who have more than a 30-pack-year smoking history, who are between 55 and 74 years of age, and who are current smokers or have stopped smoking within the past 15 years (NCCN, 2014). Table 1 defines the different risk categories. Additional risk factors that could raise the risk status are also included, such as radon or other occupational exposures.

In 2011, the National Lung Screening Trial (NLST) estimated that there were about 7 million people in the United States who would meet high-risk eligibility criteria for lung cancer screening. However, an estimated 45.3 million people in the United States (19.3% of all adults) are current smokers (Centers for Disease Control and Prevention [CDC], 2013a). About 34.6% of adults with less than a high school education are current smokers, and 13.2% of adults with a college degree are current smokers (CDC, 2013b).

Tobacco use, which continues to be the single greatest risk factor for lung cancer, is associated with a 20-fold increase in the risk of developing lung cancer. Lung cancer screening must never replace or be offered without smoking cessation education. There is concern that lung cancer screening will be used as an excuse for patients to continue smoking (Wender et al., 2013), as those who receive a negative result from screening may have a false sense of security. Gomez and LoBiondo-Wood (2013) summarized the current literature on the effects of lung cancer screening on smoking cessation rates. They concluded that trial participants (both in the screening and control arms) were more likely to stop smoking compared with the general population.

EVIDENCE-BASED SCREENING GUIDELINES

Various methods for lung cancer screening have been studied, including sputum testing, chest x-ray, and computed tomography (CT), but the most effective method has been shown to be screening with low-dose CT scans.

OLDER TRIALS

The Early Lung Cancer Action Project (ELCAP) found that low-dose CT can improve the detection of early lung cancer (Henschke et al., 1999). In 2006, results of a large collaborative lung cancer screening study were published in The New England Journal of Medicine (International Early Lung Cancer Action Program Investigators, 2006). This study followed over 30,000 asymptomatic persons at risk for lung cancer who underwent low-dose CT scanning. The investigators concluded that annual spiral CT screening can detect curable lung cancers. Prior to this study, a significant concern was whether such screening and early intervention were sufficiently effective to justify screening large asymptomatic at-risk populations. This study found that lung cancer detection rates were similar...
to or slightly higher than rates of detection in the breast cancer screening setting. Cost-effectiveness was also noted to be positive and similar to that associated with mammography screening.

Another study found that although low-dose CT screening might increase the rate of lung cancer detection, it might not reduce the risk of advanced lung cancer or mortality from lung cancer (Bach et al., 2007).

NATIONAL LUNG SCREENING TRIAL

New guidelines recommending lung cancer screening in certain high-risk populations are based on data derived from the NLST (Detterbeck, Mazzone, Naidich, & Bach, 2013; Gomez & LoBiondo-Wood, 2013; NCCN, 2014; Wender et al., 2013). Table 2 summarizes the population criteria recommended for lung cancer screening.

These factors also defined the criteria for entrance into the NLST (NLST Research Team, 2011), funded by the National Cancer Institute. Individuals with a previous diagnosis of lung cancer, previous CT scanning within 18 months, hemoptysis, or unexplained weight loss were excluded. Over 53,000 people at high risk for lung cancer were enrolled across 33 US medical centers and randomly assigned to receive three annual screenings with either low-dose CT or single-view posteroanterior chest radiography. Data showed that low-dose CT screening reduced mortality from lung cancer by 20%.

A COMPREHENSIVE, COORDINATED CARE PROCESS

Counseling about the risks and benefits of lung cancer screening prior to actual screening is recommended (Detterbeck et al., 2013). Issues to be discussed during counseling are described in Table 3. Knowing the risks and benefits of lung cancer screening will enable patients to make more informed decisions. It is difficult to quantify some risk, such as psychological concerns or the impact of radiation exposure. Overdiagnosis is also a risk: The identification of a small, indeterminable, likely benign nodule (too small to biopsy) may lead to unnecessary worry and an invasive procedure for something that might never become symptomatic during a patient’s lifetime (Boiselle, 2013). Perceptions of risk and fears of cancer are widely varied, highlighting the importance of individual decision-making with appropriate education (Park et al., 2013).

Lung cancer screening should be conducted in a multidisciplinary setting (Detterbeck et al., 2013; Wender et al., 2013). This would include certified radiologists and radiologic technologists with additional training/expertise in screening image quality and interpretation (NLST Research Team, 2011). Quality metrics similar to those used for mammography must be developed. A comprehensive, coordinated care process is required for patient selection, patient counseling, smoking cessation intervention, screening, image interpretation, management of findings (including referral

---

### Table 1. Definitions of Lung Cancer Risk

| Risk category | Definition |
|---------------|------------|
| High          | • Smoking history: ≥ 30 pack-years<br>• Current smoker or stopped within past 15 yr<br>• Ages 55–74 yr OR ≥ 50 years of age, ≥ 20 pack-years, and 1 additional risk factor |
| Moderate      | • Smoking: ≥ 20 pack-year history (or second-hand smoke exposure)<br>• Age ≥ 50 yr<br>• No additional risk factors |
| Low           | • < 50 yr AND/OR<br>• Smoking: < 20 pack-year history |

**Additional risk factors**

• Documented radon exposure
• Occupational exposure (silica, cadmium, asbestos, arsenic, beryllium, chromium, diesel fumes, nickel, coal smoke, soot)
• Cancer history (lung, lymphomas, head and neck, or other smoking related cancers)
• Chronic lung disease (COPD or pulmonary fibrosis)
• Second-hand smoke exposure

**Note.** COPD = chronic obstructive pulmonary disease. Information from NCCN (2014), National Lung Screening Trial Research Team (2011).

* Patients with signs or symptoms of lung cancer (such as unexplained weight loss of > 15 lb in last year and/or hemoptysis) are not candidates for screening, but should be appropriately evaluated.

---

### Table 2. Population Criteria Recommended for Lung Cancer Screening

| Criteria                                      |
|----------------------------------------------|
| • Age between 55–74 yr*                      |
| • ≥ 30 pack-years of smoking                 |
| • If former smoker, must have quit within the past 15 years |

**Note.** *The American Association for Thoracic Surgery recommends ages 55–79.
to multidisciplinary team if indicated), and data collection. A formal procedure for the evaluation of any lung nodules must be defined as predetermined algorithms. This step will minimize unnecessary imaging and biopsies (Detterbeck et al., 2013). At this time, the duration of screening is unknown; the NLST performed three annual screenings (NLST Research Team, 2011).

**THE ROLE OF THE ADVANCED PRACTITIONER**

The advanced practitioner (AP) in oncology has an important role in screening for lung cancer. It is unknown whether primary care practitioners will be able to assume a major role in this process (Detterbeck et al., 2013). Education of members of the public, professionals, and insurers is vital to the screening process. Resources for the AP, including educational materials and information on tobacco cessation, are listed in the upper section of Table 4. The lower section of Table 4 offers some resources that may assist in patients’ understanding of the screening process and its implications.

Advanced practitioners may be consulted regarding who is at risk and who qualifies for screening. Counseling about potential benefits and potential harms is within the scope of the AP as well. Smoking cessation counseling may also be

---

**Table 3. Lung Cancer Screening Precounseling**

| Risks of screening | Benefit of screening |
|--------------------|----------------------|
| False positives that may result in unnecessary tests/biopsies | Early detection of a potential curable cancer |
| False negatives that may result in missing a cancer | |
| Anxiety and fear | |
| Radiation exposure | |
| Financial cost/burden to patient/public | |
| Overdiagnosis | |

*Note. Information from From Boiselle (2013), Detterbeck et al. (2013), Wender et al. (2013).*

---

**Table 4. Lung Cancer Screening Resources**

| Professional Resources | Patient Resources |
|------------------------|-------------------|
| National Cancer Institute Lung Cancer Screening PDQ | American Cancer Society: Testing for Lung Cancer in People at High Risk (patient page) |
| www.cancer.gov/cancertopics/pdq/screening/lung/HealthProfessional | http://onlinelibrary.wiley.com/doi/10.3322/caac.21177/pdf |
| National Tobacco Cessation Collaborative (tools and resources for clinicians) | American Lung Association, Lung Cancer CT Screening, Is It Right for me? |
| www.tobacco-cessation.org/resources/tools.html | www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-cancer-screening-for-patients.pdf |
| Smoking Cessation Leadership Center (smoking cessation tools and resources) | American Lung Association Online Screening Tool for Patients |
| http://smokingcessationleadership.ucsf.edu/Resources.htm | www.lung.org/about-us/our-impact/top-stories/new-lung-cancer-screening.html |
| US Preventive Services Task Force Lung Cancer Screening (update in progress) | ASCO, Cancer.net, Lung Cancer Screening |
| www.uspreventiveservicestaskforce.org/uspstf/uspslung.htm | www.cancer.net/publications-and-resources/asco-care-and-treatment-recommendations-patients/lung-cancer-screening |
| | Memorial Sloan Kettering Cancer Center Lung Cancer Screening Decision Tool |
| | http://nomograms.mskcc.org/Lung/Screening.aspx |
| | NCCN Guidelines for Patients: Lung Cancer Screening (online booklet) |
| | www.nccn.org/patients/guidelines/lung_screening/index.html |
| | SmokeFree.Gov (free information and resources) |
| | www.smokefree.gov/ |
| | Time and Cost of Smoking Calculator |
| | www.hellohaveyouheard.com/lung-cancer-risk-assessment/ |
| | WebMD, Are You Ready to Quit Smoking? (interactive tool) |
| | www.webmd.com/smoking-cessation/tc/interactive-tool-are-you-ready-to-quit-smoking-what-does-this-tool-measure |
performed by the oncology AP. The AP may be influential in obtaining insurance coverage for lung cancer screening. Further research is also needed to define the screening model and to answer questions regarding the duration of screening, cost-effectiveness, and effect upon lung cancer mortality.

Disclosure
The author has no potential conflicts of interest to disclose.

References
Bach, P., Jett, J., Pastorino, U., Tockman, M., Swensen, S., & Begg, C. (2007). Computed tomography screening and lung cancer outcomes. *Journal of the American Medical Association, 297*(9), 953–961. http://dx.doi.org/10.1001/jama.297.9.953

Boiselle, P. (2013). Computed tomography screening for lung cancer. *Journal of the American Medical Association, 309*(11), 1163–1170. http://dx.doi.org/10.1001/jama.2012.216988

Centers for Disease Control and Prevention. (2013a). Adult cigarette smoking in the United States: Current estimate. Retrieved from http://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm

Centers for Disease Control and Prevention. (2013b). Cigarette smoking—United States, 2006-2008 and 2009-2010. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/su6203a14.htm?s_cid=su6203a14_w

Detterbeck, F., Mazzone, P., Naidich, D., & Bach, P. (2013). Screening for lung cancer. *Chest, 143*(5), 785–92S. http://dx.doi.org/10.1378/chest.12-2350

Gomez, M., & Lobiondo-Wood, G. (2013). Lung cancer screening with low-dose CT: Its effect on smoking behavior. *Journal of the Advanced Practitioner in Oncology, 4*(6), 405–414.

Henschke, C., McCauley, D., Yankelevitz, D., Naidich, D., McGuinness, G., Miettinen, O.,...Pasmantier, M., et al. (1999). Early lung cancer action project: Overall design and finding from baseline screening. *Lancet, 354*(9173), 99–105. http://dx.doi.org/10.1016/S0140-6736(99)60693-6

International Early Lung Cancer Action Program Investigators, Henschke, C., Yankelevitz, D., Libby, D., Pasmanter, M., Smith, J., & Miettinen, O. (2006). Survival of patients with stage I lung cancer detected on CT screening. *New England Journal of Medicine, 355*(17), 1763–1771. http://dx.doi.org/10.1056/NEJMoa060476

National Lung Screening Trial Research Team, Aberle, D., Adams, A., Berg, C., Black, W., Clapp, J., Fagerstrom, R.,...Sicks, J. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. *New England Journal of Medicine, 365*(5), 395–409. http://dx.doi.org/10.1056/NEJMoal102873

National Comprehensive Cancer Network. (2014). NCCN Clinical Practice Guidelines in Oncology: Lung cancer screening, Version 1.2014. Retrieved from www.nccn.org

Park, E., Strech, J., Gareen, H., Ostroff, J., Hyland, K., Rigotti, N.,...Nichter, M. (2013). A qualitative study of lung cancer risk perceptions and smoking beliefs among national lung screening trial participants. *Nicotine & Tobacco Research, 16*, 166–173. http://dx.doi.org/10.1093/ntr/ntt133

Wender, R., Fontham, E., Barrera, E., Colditz, G., Church, T., Ettinger, D.,...Etzioni, R. (2013). American Cancer Society Lung Cancer Screening Guidelines. *CA Cancer Journal for Clinicians, 63*, 106–117. http://dx.doi.org/10.3322/caac.21172